NEWS RELEASE
Novation First To Have A National Agreement With Boston Scientific For The Promus™ Everolimus-Eluting Stent
IRVING, TX; July 14, 2008 — Novation, the health care industry’s leading contracting services company of VHA Inc. and the University HealthSystem Consortium (UHC), today announced that it has added the Boston Scientific PROMUS everolimus-eluting stent to its national agreement. On contract with Novation the day after receiving Federal Drug Administration (FDA) approval, it is the newest cobalt drug-eluting coronary stent on the U.S. market.
PROMUS is immediately available in diameters of 2.5 mm, 2.75 mm, 3.0 mm, 3.5 mm and 4.0 mm. The available stent lengths are 8, 12, 15, 18, 23 and 28 mm. The device will be available in both rapid-exchange and over-the-wire delivery system designs.
The contract is effective July 3, 2008 - Sept. 30, 2010.
###
About Novation
Founded in 1998, Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances, and 5,500 members of Provista, LLC, representing 28,000 sites. Novation provides alliance members contract and price management and spend management services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $37.8 billion in 2009.
Media Contact
Kathryn Goldstein
Director, Public Relations
Novation
(972) 581-5529
kgoldste@novationco.com
|
